Denmark Sweden Norway Finland  Genzyme Norge HomeKontaktGenzyme Corporate Home
OM OSS
BEHANDLINGSOMRÅDER
PRODUKTER
Genzyme  
Genzyme er et av verdens ledende bioteknologiske firmaer og vårt mål er å forbedre livet for pasienter med alvorlige sykdommer. Les mer her
 

NYHETER
Genzyme Announces Enrollment of First Patient in Phase II Vatelizumab Trial in Relapsing Remitting Multiple Sclerosis

Cambridge, Mass. - Nov. 4, 2014 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today enrollment of the first patient in a multicenter Phase II clinical trial to evaluate Genzyme’s investigational infusion therapy vatelizumab in patients with relapsing remitting multiple sclerosis (RRMS). The trial, called EMPIRE, is designed to assess the efficacy of vatelizumab vs. placebo in RRMS patients. The safety, tolerability and pharmacokinetics of vatelizumab will also be assessed.
Mere >
FDA Approves Genzyme’s Cerdelga (eliglustat) Capsules - Only First-Line Oral Treatment for Adult Gaucher Disease Type 1

CAMBRIDGE, Mass.—Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only first-line oral therapy for certain adult Gaucher disease type 1 patients. A small number of adult patients who metabolize Cerdelga more quickly or at an undetermined rate, as detected by an established genetic laboratory test, will not be eligible for Cerdelga treatment. Cerdelga is expected to be available to patients within a month.
Mere >
Genzyme Recognizes Sixth Annual World MS Day

Cambridge, Mass. - May 28, 2014 - Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today recognizes World MS Day, an initiative developed by the Multiple Sclerosis International Federation (MSIF) to raise awareness of MS and its impact on the lives of more than two million people around the world. With two differentiated MS therapies and a research pipeline focused on innovative approaches to treating the disease, Genzyme has a long-term commitment to the MS community.
Mere >
FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy for Gaucher Disease - - Second Major Regulatory Filing Following EMA Acceptance in Late October -

Cambridge, Mass – December 11, 2013 – Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the Food and Drug Administration (FDA) has granted Priority Review designation to its New Drug Application (NDA) for Cerdelga™ (eliglustat), an investigational oral therapy for adult patients with Gaucher disease type 1. As previously announced, the European Medicines Agency in late October validated Genzyme’s marketing authorization application (MAA) for eliglustat in the EU.
Mere >

GENZYME
BIOSURGERY
GENZYME
GLOBALT
GENZYME
CORPORATION

Invitert til ett av våre arrangementer? Påmelding her: vsanofi.linkevent.no
 

Terms and Conditions Privacy Policy © 2008 Genzyme. All Rights Reserved. Webmaster